SCHEMBL22897214

SCHEMBL22897214

Cc1cccc(-c2nn(C)cc2C(=O)NC(Cc2ccccc2)C(O)C(N)=O)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DCAF1 Q9Y4B6 1/20 0.51
▸ PYGL P06737 2/20 0.46
▸ CTSV O60911 1/20 0.44
▸ CTSL P07711 1/20 0.44
▸ CTSS P25774 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ HPGDS O60760 1/20 0.40
▸ F2 P00734 2/20 0.39
▸ F10 P00742 2/20 0.39
▸ PRSS1 P07477 2/20 0.39
▸ PRSS2 P07478 2/20 0.39
▸ PRSS3 P35030 2/20 0.39
▸ CMA1 P23946 2/20 0.39
▸ CTRC Q99895 2/20 0.39
▸ KLKB1 P03952 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20028717 0.90 DCAF1 (0.50) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL22885968 0.88 DCAF1 (0.49) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL22885969 0.87 DCAF1 (0.48) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL22897243 0.87 DCAF1 (0.51) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL20027718 0.87 DCAF1 (0.51) DCAF1PYGLCTSVCTSLCTSS
SCHEMBL30133636 0.85 DCAF1 (0.54) DCAF1CTSVCTSLCTSSCTSK
SCHEMBL20027973 0.85 DCAF1 (0.54) DCAF1CTSVCTSLCTSSCTSK
SCHEMBL21854222 0.85 DCAF1 (0.54) DCAF1CTSVCTSLCTSSCTSK
SCHEMBL20027914 0.84 DCAF1 (0.48) DCAF1PYGLALDH1A1CSNK1D
SCHEMBL20027617 0.83 PYGL (0.43) DCAF1PYGLCTSVCTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 — — US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 — — US disclosed
US-10894776-B2 — — 2021-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 DCAF1 3091/4885PYGL 925/4885CTSV 314/4885
US-10894776-B2 — CAPNS1, CAPN9, CAPN2 DCAF1 3598/4885PYGL 668/4885CTSV 359/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 DCAF1 3091/4885PYGL 925/4885CTSV 314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback